Krystal Biotech, Inc. (KRYS)
NASDAQ: KRYS · Real-Time Price · USD
303.06
+2.18 (0.72%)
At close: Nov 9, 2026, 4:00 PM EST
306.56
+3.50 (1.15%)
Pre-market: Nov 10, 2026, 7:34 AM EST
Krystal Biotech Stock Forecast
Stock Price Forecast
According to 12 analysts polled by S&P Global, Krystal Biotech stock has a consensus rating of "Strong Buy" and an average price target of $388.22. The average 1-year stock price forecast is 28.10% higher than the current stock price, while the lowest is $284 (-6.29%) and the highest is $474 (+56.40%).
Price Target: $388.22 (+28.10%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Krystal Biotech stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jun '26 | Jul '26 | Aug '26 | Sep '26 | Oct '26 | Nov '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 10 | 9 | 9 | 10 | 10 | 10 |
| Buy | 0 | 0 | 1 | 1 | 1 | 1 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 11 | 10 | 11 | 12 | 12 | 12 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| RBC Capital | RBC Capital | Buy Reiterates $375 | Buy | Reiterates | $375 | +23.74% | Nov 6, 2026 |
| TD Cowen | TD Cowen | Buy Maintains $403 → $380 | Buy | Maintains | $403 → $380 | +25.39% | Nov 3, 2026 |
| Bank of America Securities | Bank of America Securities | Buy Reiterates $400 → $390 | Buy | Reiterates | $400 → $390 | +28.69% | Nov 3, 2026 |
| Citi | Citi | Buy Maintains $416 → $412 | Buy | Maintains | $416 → $412 | +35.95% | Nov 3, 2026 |
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $361 | Buy | Reiterates | $361 | +19.12% | Nov 2, 2026 |
Financial Forecast
Revenue This Year
497.46M
from 389.13M
Increased by 27.84%
Revenue Next Year
634.85M
from 497.46M
Increased by 27.62%
EPS This Year
8.01
from 6.84
Increased by 17.12%
EPS Next Year
9.23
from 8.01
Increased by 15.19%
EPS and Forward PE are based on non-GAAP adjusted numbers.